Impel Pharmaceuticals Inc (IMPL) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Impel Pharmaceuticals Inc   (NASDAQ: IMPL)

Impel Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Impel Pharmaceuticals Inc in the third quarter 2023?
Due to the lack of equity, it was not possible to calculate Impel Pharmaceuticals Inc 's return on equity (ROE) in its third quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -74 -92 -109 -106 -108
Return On Equity (TTM) - - - - -701.26 %
IMPL's Total Ranking # # # # #
Equity (TTM) in Millions -92 -79 -73 -44 -22
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to IMPL Management Effectiveness >> IMPL's 5 Years Annual ROE >> Compare IMPL ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





IMPL Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021


Total Equity in Millions -44 53 0 0 0
Y / Y Equity Change - - - - -
Net Income in Millions -106 -77 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity - -145.76 % - - -

Back to IMPL Management Effectiveness >> IMPL's 5 Years Annual ROE >> Compare IMPL ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IMPL's' Return on Equity at Yahoo Finance
IMPL's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IMPL's Competitors
Subscribers only: Roe for Impel Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for IMPL's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE
Tff Pharmaceuticals Inc  242.93 %
Therapeuticsmd Inc   216.13 %
Scynexis Inc   182.33 %
Biomx Inc  173.61 %
Halozyme Therapeutics Inc   159.73 %
Inhibitor Therapeutics Inc   141.82 %
Amgen Inc   129.08 %
Waters Corporation  119.99 %
Glucotrack Inc   93.47 %
Lite Strategy Inc   87.24 %
Idexx Laboratories Inc  85.68 %
Dariohealth Corp   76.80 %
Davita Inc   76.14 %
Medpace Holdings Inc   68.48 %
Opus Genetics Inc   65.54 %
Protalix Biotherapeutics inc   62.80 %
Gyre Therapeutics Inc   62.04 %
Cv Sciences Inc   56.96 %
Elite Pharmaceuticals Inc   55.08 %
Omeros Corporation  54.32 %
Vaso Corporation  50.49 %
Zoetis Inc   49.00 %
Enzo Biochem Inc  47.55 %
Star Equity Holdings Inc   47.18 %
Abbvie Inc   46.90 %
Johnson and Johnson  46.90 %
Eli Lilly And Company  44.81 %
Zymeworks Inc   44.62 %
Escalon Medical Corp   42.84 %
Entera Bio Ltd   42.52 %

Date modified: 2026-09-08T15:11:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.